Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392608 | 0.93 | HPGD (0.44) | PKMSIGMAR1MAPK14HPGDADORA2A | |
| Trifluoroacetic Acid SCHEMBL31161877 | 0.92 | GABRD (0.46) | DDR1 | |
| Trifluoroacetic Acid SCHEMBL31161289 | 0.91 | LRRK2 (0.43) | PKML3MBTL1HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL30392394 | 0.89 | DDR1 (0.40) | HPGDDDR1HSD11B1GPR6 | |
| Trifluoroacetic Acid SCHEMBL30392637 | 0.87 | GPR6 (0.38) | L3MBTL1HPGDDDR1HSD11B1GPR6 | |
| Trifluoroacetic Acid SCHEMBL30392313 | 0.87 | HSD11B1 (0.40) | L3MBTL1HPGDDDR1HSD11B1GPR6 | |
| Trifluoroacetic Acid SCHEMBL31161704 | 0.87 | CACNA2D1 (0.39) | SIGMAR1DDR1HSD11B1GPR6KCNH2 | |
| SCHEMBL30014379 | 0.85 | GABRD (0.51) | — | |
| SCHEMBL25596266 | 0.85 | GABRD (0.51) | — | |
| Trifluoroacetic Acid SCHEMBL31255479 | 0.85 | PKM (0.57) | PKMRAD52UBE2NL3MBTL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | PKM 1429/4885RAD52 937/4885UBE2N 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.